Johnson & Johnson
Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About JNJ
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments.
JNJ Key Statistics
JNJ News
Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump...
Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our P/B Growth Investor mod...
Johnson & Johnson announced plans to initiate the first head-to-head study comparing FcRn blockers for patients with generalized myasthenia gravis, or gMG, whic...
Analyst ratings
56%
of 27 ratingsMore JNJ News
Texas Attorney General Ken Paxton has filed a lawsuit against Johnson & Johnson (NYSE:JNJ) and Kenvue Inc (NYSE:KVUE), accusing the companies of misleading preg...
After Texas Attorney General Ken Paxton announced he has sued Johnson & Johnson (JNJ) and Kenvue (KVUE) for marketing Tylenol to pregnant mothers, Citi analyst...
Kenvue (KVUE) stock fell on Tuesday after Texas Attorney General Ken Paxton filed a lawsuit against the company over allegations that Tylenol is tied to autism....
Deciding what to do with Johnson & Johnson stock these days is a lot like weighing your options at a crossroads. From long-time holders to investors peering in...
In early trading on Tuesday, shares of Sherwin-Williams topped the list of the day's best performing Dow Jones Industrial Average components, trading up 7.5%. Y...
H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Protagonist Therapeutics today and set a price target of $80.00. Elevate Your Investing Strategy...
In recent days, Protagonist Therapeutics announced encouraging Phase 2b clinical data for icotrokinra, its IL-23 receptor antagonist, which demonstrated sustain...
